Skip to main content

Study of the efficacy and safety of inhaled Treprostinil in patients with Idiopathic Pulmonary Fibrosis

Research Question:
The purpose of this study is to evaluate the safety and efficacy of inhaled Treprostinil in subjects with IPF.

Basic Study Information

You are being asked to be in this research study because you have idiopathic pulmonary fibrosis (IPF). This means that you have scarring of the lungs from an unknown cause. The scarring makes it hard for the lungs to get oxygen into the blood, which causes shortness of breath and coughing. This research study is being conducted under the direction of R. Matthew Kottmann, MD, MS-CTR who is the “principal investigator,” also known as the “study doctor.” As the study doctor, Dr. Kottmann is solely responsible for making sure that this study is done properly and that your rights and safety, as a participant in this study are protected. Dr. Kottmann will carry out the day-to-day activities of the research study in accordance with his independent medical judgment. United Therapeutics Corp., a drug company, is the “sponsor” of this research study and is responsible for the development and broad oversight of the study.

Study Web URL:
Study Reference #: STUDY00006294

Lead Researcher (Principal Investigator)

Lead Researcher:  Robert Kottmann

Study Contact Information

Additional Study Details

Number of Visits:  6 to 10
Parking:  Reimbursed
Transportation Coverage:  No
Reimbursement:  No

Learn More About These Conditions

More information about Idiopathic Pulmonary Fibrosis

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search